Skip to main content

Topic

Biosimilars

856 published works

  1. Big Molecule Watch

    Alvotech’s BLA for Vedolizumab Biosimilar First to be Accepted by FDA

    By Zachariah Holmes

    On June 8, Alvotech announced that the U.S. Food and Drug Administration (“FDA”) has accepted Alvotech’s Biologics License Application (“BLA”) for AVT16, a proposed interchangeable biosimilar to Takeda’s ENTYVIO (vedolizumab),…

  2. Big Molecule Watch

    Chime Biologics and Daewoong Pharmaceutical Partner on Dupilumab Biosimilar

    By Timothy Beavers

    On June 2, 2026, Chime Biologics and Daewoong Pharmaceutical announced a strategic partnership agreement for the development and manufacturing of a dupilumab biosimilar candidate referencing Sanofi and Regeneron’s DUPIXENT. Chime…

  3. Big Molecule Watch

    Boan Biotech Submits BLA to FDA for Two Denosumab Biosimilars

    By Alice Yoon

    On May 29, 2026, Boan Biotech announced that it submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for BA6101 (denosumab; injection 60 mg) and…

  4. Big Molecule Watch

    Polpharma and Tuteur Enter License for the Commercialization of a Biosimilar Targeting Autoimmune Diseases in Latin America

    By Riley Wyberg

    On May 22, 2026, Polpharma Biologics announced that it had entered into an exclusive licensing agreement with Tuteur to commercialize a biosimilar targeting autoimmune diseases across Latin America, excluding Brazil. …

  5. Big Molecule Watch

    Samsung Bioepis Launches OPUVIZ in Europe

    By Harrison Gunn

    On May 29, 2026, Samsung Bioepis Co., Ltd. announced the European launch of OPUVIZ, a biosimilar referencing EYLEA (aflibercept). OPUVIZ will be available as a 40 mg/mL solution for injection.…

  6. Big Molecule Watch

    CHMP Adopts Positive Opinion for Ranibizumab Biosimilars VISLYFA and REXATILUX

    By Alison Siedor

    The EMA’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for two ranibizumab biosimilars, VISLYFA and REXATILUX, recommending granting of a marketing authorization.  Ranibizumab is…

  7. Big Molecule Watch

    FDA Approves Shanghai Henlius Biotech IND for Cetuximab Biosimilar

    By Natasha Daughtrey

    On May 10, 2026, Shanghai Henlius Biotech announced that the FDA has approved its IND for a proposed biosimilar, HLX05-N, to Eli Lilly’s ERBITUX (cetuximab) product for the treatment of metastatic…

  8. Big Molecule Watch

    FDA Approves First Interchangeable Biosimilars to Simponi and Simponi Aria; Janssen Seeks a Preliminary Injunction to Block Their Launch

    By Sarah Adam

    On May 15, 2026, the U.S. Food and Drug Administration (“FDA”) approved Accord BioPharma’s IMMGOLIS (golimumab-sldi) as an interchangeable biosimilar to Janssen’s SIMPONI® (golimumab), and IMMGOLIS INTRI (golimumab-sldi) as an…

  9. Big Molecule Watch

    International Biosimilars Updates

    By Riley Wyberg

    On April 21, 2026, Biocon announced that Health Canada granted a Notice of Compliance (NOC) for BOSAYATM (denosumab) and VEVZUOTM (denosumab), biosimilars of Amgen’s Prolia® (denosumab) and Xgeva® (denosumab). Denosumab…

  10. Big Molecule Watch

    Third Circuit Affirms Denial of Stelara Biosimilar Injunction

    By Alison Siedor

    As previously reported, litigation between Johnson & Johnson and Janssen (“J&J”) and Samsung Bioepis (“Samsung”) involving Samsung’s Stelara biosimilar, PYZCHIVA (ustekinumab-ttwe) (previously known as SB17), was resolved via a settlement…